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Abstract
Background: Bipolar disorder (BD) is a major psychiatric condition that commonly requires
prophylactic and episodic treatment. Lithium (Li) has been used for over 40 years now as an
effective prophylactic agent. Response to Li treatment seems to be, at least in part, genetically
determined. Although we ignore how Li specifically prevents mood episodes, it has previously been
suggested that Li exerts an effect on the phosphoinositide pathway, and more recently, it has been
proposed that Li may modulate prolyl endopeptidase (PREP).
Methods: In this study we carried out an association study looking at the PREP gene, located on
ch 6q22. Five intronic single nucleotide polymorphisms (SNP), three coding SNPs and one SNP in
the 5' UTR were investigated for their frequency in a BD sample of 180 excellent Li responders,
69 Li nonresponders and 126 controls. Genotyping was carried out using the SNaPshot reaction
from Applied Biosystems, which is a modified fluorescent single base pair extension procedure.
Results: Following correction for multiple testing, no significant genotypic, allelic or estimated
haplotypic differences were found between responders and nonresponders or between BD
patients and controls.
Conclusion: PREP is an interesting candidate gene to investigate in genetic studies of BD, but our
findings do not support the hypothesis that genetic variation in this gene plays a major role in the
etiology of BD or Li response.
Background
Lithium has been one of the most widely used and best
characterized prophylactic treatments for bipolar disorder
(BD). Even though the therapeutic effects of lithium have
been well documented for many years, its mechanism of
action remains unknown. Several plausible pathways
have been hypothesized to be influenced by lithium; the
phosphoinositide pathway being one [1]. It has been
demonstrated that lithium inhibits two key enzymes
involved in the regeneration of free inositol. One of these
is inositol monophosphatase (IMPase), which is the
enzyme responsible for the conversion of inositol mono-
phosphate (IMP) to free inositol. The other one is inositol
polyphosphatase (IPP), which is the enzyme catalyzing
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the transformation of inositol 1,4-bisphosphate to IMP
[2,3]. The effects of the lithium induced inhibition results
in the decrease of phosphatidyl inositol-4,5-bisphosphate
(PIP2). This subsequently causes a decrease in the down-
stream signaling molecules, inositol-1,4,5-trisphosphate
(IP3) and diacylglycerol (DAG) which are produced
through the phospholipase C catalyzed breakdown of
PIP2. This process initiates a dampening of cellular
response to second messengers [4]. It is for this reason
that genes involved in this pathway are good candidates
for investigation
One such gene is prolyl endopeptidase or prolyl oli-
gopeptidase (PREP). Prolyl endopeptidase has been
shown to be highly active in the brain, especially in the
frontal cortex and in the limbic system [5,6]. PREP is a
cytosolic serine protease that has been shown to cleave
neuropeptides made up of 30 residues or less, for instance
thyrotropin-releasing hormone, arginine vasopressin, and
others [7]. Investigating possible mechanisms of lithium's
action in Dictyostelium, an amoebae used as a model sys-
tem for molecular genetic studies, Williams and col-
leagues (1999) reported that lithium resistant mutants
lacked the PREP gene and showed high levels of IP3. This
increase is likely the result of the inability of Dictyostel-
ium to dephosphorylate IP3 into IP2. Thus, these results
provided experimental evidence for a link between the
lack of PREP expression and increased IP3 levels. In addi-
tion, this data adds evidence to the implication of the
inositol second-messenger system in BD and lithium's
mode of action. These findings are in accordance with a
previously reported association between abnormal PREP
activity and bipolar disorder/major depression [8].
Recently, Williams et al. [9] added new results suggesting
a common, underlying mechanism via inositol depletion
for lithium, valproic acid and carbamazepine, all com-
monly used mood stabilizers for bipolar disorder. The
authors showed that Dictyostelium resistance in mutants
to these drugs was conferred by PREP, further suggesting a
possible role of prolyl endopeptidase as a mediator of
these drugs' mood stabilizing action through the inositol
system.
Interestingly, the PREP gene is located on chromosome
6q22, a region that has been linked to BD in several stud-
ies [10-12] and most recently in Portuguese families [13-
15], thus providing added incentive to investigate genes in
this chromosomal region.
The purpose of this paper was to investigate variation at
the PREP  gene in a sample of BD patients with either
excellent lithium response or nonresponse.
Methods
Subjects
The sample used for this study was composed of 251
patients with only a diagnosis of BD. Of these patients, a
hundred forty-five patients were females and 104 were
male, with a mean age of 47.91 ± 14.09 years and a mean
age of onset of 26.15 ± 9.71. Of the cases 180 were
responders (LiR) and 69 were nonresponders (LiNR) to
long term lithium treatment. All psychiatric assessments
were carried out by experienced clinicians using the SADS-
L structured interviews, and the RDC and DSM-IV criteria.
Excellent lithium response was established as described
previously [16] and summarized in Table 1, with the
number of pretreatment episodes (± standard deviation)
being 8.04 ± 5.75 and treatment length being 13.25 ± 7.26
years. Controls included in this study were 126 healthy,
psychiatrically normal individuals (mean age 48.17 ±
11.84) that were assessed using the same criteria as for
patients. Prior to inclusion in the study, all individuals
provided written informed consent. This study was
approved by the local review boards of each institution.
All subjects included in this study were Caucasian of Euro-
pean origin that were recruited in centers that are part of
the International Group for the Study of Lithium (IGSLi),
a collaborative group of specialized clinics in Canada,
Austria, Czech Republic, Denmark, Germany, and Swe-
den. To ensure diagnostic uniformity across the clinics all
patients were subsequently evaluated by the same senior
clinician (PG).
DNA analysis
Genomic DNA was extracted using a standardized
method (Sambrook et al, 1989) from venous blood sam-
ples. Nine single nucleotide polymorphisms (SNP), five
intronic, three coding and one located in the 5' UTR,
spaced out along the PREP gene were investigated using
the ABI SNaPshot multiplex reaction and the ABI 3100
automated genetic analyzer (Figure 1). Polymerase chain
reaction (PCR) was carried out in a total volume of 15 μl
which contained 30 ng genomic DNA, 0.2 μM of each
primer, 0.25 mM of each dATP, dNTP, dTTP and dGTP,
0.75 units of Amplitaq Gold DNA polymerase, 1.5 μl of
10× buffer and 25 mM MgCl2. The samples were put
through between 30 to 40 cycles of denaturation at 94°C,
annealing at specific primer temperatures, elongation at
72°C and a final extension at 72°C. PCR product ampli-
fication was verified by running 5 μl of product on a 2%
agarose gel. The remaining product was then processed as
per the ABI SNaPshot protocol, using primers designed for
fluorescent dideoxy nucleotide termination. SNP analysis
was carried out on the ABI 3100 genetic analyzer. Geno-
types were determined automatically using the Genemap-
per software (Applied Biosystems).BMC Psychiatry 2007, 7:9 http://www.biomedcentral.com/1471-244X/7/9
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Statistical analysis
Hardy-Weinberg (HW) analysis was carried out using the
Quick Chi program and those SNPs found to be in dise-
quilibrium were not included in further analyses. Allelic
and genotypic frequency distributions were compared
between cases and controls, responders versus controls,
nonresponders versus controls and finally responders ver-
sus nonresponders using a χ2 test and the computer pro-
grams SigmaStat and SPSS. Haplotype and linkage
disequilibrium (LD) analyses were carried out using both
GENECOUNTING and its support programs [17,18]. Our
sample had 85% power to detect an association with a
variant that is present in 35% of the general population
and that doubles the likelihood of lithium response,
assuming a type I error no greater than 5%.
Results
Table 2 outlines the genotypic and allelic distribution and
respective χ2 values for the 8 loci investigated; the PREP3
SNP was disregarded because it was in HW disequilib-
rium. Upon completion of analyses several positive
results were found prior to correction for multiple testing,
interestingly only when the lithium responder subgroup
was included in the analysis. When comparing cases and
controls the PREP6 GG genotype was significantly associ-
ated with BD (p = 0.026). This genotype was also found to
be significantly associated with response when LiR were
compared to LiNR (p = 0.040) or to controls (p = 0.003).
Furthermore, in the comparison of responders with con-
trols, the G allele was significantly associated with LiR (p
= 0.011).
For PREP8 both genotypic and allelic associations were
found to be significantly associated with lithium response
(GA, χ2 = 7.008, df = 2, p = 0.03; A, p = 0.012). PREP9 pro-
vided significant genotypic and allelic associations in the
following comparisons; LiR vs. controls (TT, χ2 = 6.234, df
= 2, p = 0.044; T, p = 0.035) and LiR vs. LiNR (TT, χ2 =
7.664, df = 2, p = 0.022; T, p = 0.019). However, after cor-
recting for multiple testing (Bonferroni correction with 36
comparisons), these results became nonsignificant. We
did not find any association between age of onset or sex
with genotypic or allelic presentation (data not shown).
Estimated haplotype frequencies demonstrated no signif-
icant differences in any of the comparisons. Significant
linkage disequilibrium was found for most marker pair-
ings (PREP4/PREP7; D' = 0.539, p = 0.0000; PREP8/
PREP5; D' = 0.695, p = 0.0000; PREP8/PREP7; D' = 0.372,
p = 0.00901; PREP4/PREP6; D' = 0.234, p = 0.03160).
Discussion
The phosphoinositide pathway has garnered much inter-
est as a potential system housing genes involved in the eti-
ology of BD. This is mostly in part due to the inhibitory
effects of lithium on key enzymes involved in the recy-
cling and the de novo synthesis of free inositol in the cell.
A novel association between this pathway and PREP, a ser-
ine protease involved in neuropeptide breakdown has
been reported recently. Williams and collaborators in a
series of experiments were able to provide evidence
towards the existence of a common mode of action for
lithium (Li), valproate (VPA) and carbamazepine (CBZ)
implicating also PREP [9]. Their conclusions stem from
the effects seen of each drug on the plasticity of growing
neurons due to their inhibition of growth cone collapse
and an augmentation of the growth cone area [9]. This
group had previously characterized a lithium resistant
Dictyostelium mutant, with high levels of IP3 and lacking
the PREP gene [19]. With these mutants it demonstrated
that the depletion of inositol is essential for the prophy-
lactic effect of Li. This group was able to extend the inosi-
tol depletion requirement to include the function of VPA
and CBZ, further suggesting a role of PREP in the phosph-
oinositide pathway and in the efficacy of these drugs [9].
The substantiated support for the possible involvement of
PREP in the pathophysiology of BD [7-9,19] makes it a
likely candidate for investigation. In this study we looked
at nine SNPs located along the PREP gene for association
between lithium response and BD and found no differ-
ences when comparing genotypic or allelic distribution
between bipolar patients and controls or between
Table 1: Criteria used to diagnose bipolar patients as excellent lithium responders
Each patient must meet criteria A, B and C
A. Diagnosis of primary episodic bipolar disorder based on the SADS-L (lifetime version) interview and Research Diagnostic 
Criteria (RDC).
B. High Recurrence Risk
either B1: five or more episodes prior to lithium treatment
or B2: four episodes prior to lithium; of these two or more during the 2 years preceding lithium treatment
or B3: three episodes prior to lithium, plus one more within 12 months after lithium discontinuation
C. Unequivocal Lithium Response
C1: No recurrence requiring additional biological intervention (ECT, antidepressants, neuroleptics) during the entire observation time on 
lithium monotherapy
and C2: minimum period of observation of 3 years
and C3: average plasma lithium concentration over 0.6 mEq L-1BMC Psychiatry 2007, 7:9 http://www.biomedcentral.com/1471-244X/7/9
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responders and nonresponders to lithium treatment fol-
lowing correction for multiple testing.
As it is always the case with negative association studies, it
is possible that our negative results are also a consequence
of methodological limitations of this study, such as
reduced sample power to detect association with variants
accounting for small effect sizes or limited information
content of the variants investigated. In this regard, further
studies using larger samples and investigating additional
loci would be of interest. Moreover, expression studies
could also be performed looking at the levels of the PREP
protein in patients with and without good response to
lithium treatment.
Conclusion
In summary our results, albeit negative, provide an initial
look into the variation of a gene involved in the phospoi-
nositide pathway and that has been shown to play a role
in the mode of action of three common BD treatments; Li,
VPA and CBZ. The PREP gene is also housed in a region of
linkage for BD, which garners additional interest to deter-
mine its role in the etiology of BD.
SNP localization along the PREP gene Figure 1
SNP localization along the PREP gene. Location of each investigated SNP within the PREP gene with their respective 
allelic frequencies.
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PREP4 G 391 (0,968) 142 (0,922) 283 (0,969) 102 (0,962)
C 13 (0,032) 12 (0,078) 9 (0,031) 4 (0,038)
CC 2 (0,01) 2 (0,026) 1 (0,007) 1 (0,019)
GC 9 90,045) 8 (0,104) 7 (0,048) 2 (0,038)
GG 191 (0,946) 67 (0,87) 138 (0,945) 50 (0,943)
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AA 20 (0,105) 21 (0,228) 17 (0,124) 3 (0,060)
AT 82 (0,432) 31 (0,337) 62 (0,453) 20 (0,040)
TT 88 (0,463) 40 (0,435) 58 (0,423) 27 (0,54)
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GG 189 (0,875) 95 (0,922) 134 (0,887) 46 (0,821)
PREP7 A 345 (0,88) 148 (0,892) 221 (0,877) 108 (0,885)
C 47 (0,12) 18 (0,108) 31 (0,123) 14 (0,115)
AA 153 (0,781) 66 (0,795) 97 (0,77) 49 (0,803)
AC 39 (0,199) 16 (0,193) 27 (0,214) 10 (0,164)
CC 4 (0,020) 1 (0,012) 2 (0,016) 2 (0,033)
PREP8 A 282 (0,681) 123 (0,691) 174 (0,654) 95 (0,720)
G 132 (0,319) 55 (0,309) 95 (0,346) 37 (0,28)
AA 98 (0,473) 45 (0,506) 58 (0,436) 34 (0,515)
AG 86 (0,415) 31 (0,371) 58 (0,436) 27 (0,409)
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